Mumbai: Three accused in a ₹74 crore alleged fraud case being investigated by the Economic Offences Wing (EOW) of the Mumbai Police have approached the sessions court seeking anticipatory bail, marking a fresh legal development in a dispute that has evolved into a complex corporate and financial controversy involving pharmaceutical companies.
Contractual Breaches and Preemptive Bail Petitions
The case involves Emcure Pharmaceuticals, its subsidiary Zuventus Healthcare, and rival firm Zorvia Healthcare, and stems from allegations of breach of non-compete agreements, employee poaching and theft of confidential business data. The anticipatory bail applications were filed by Chandrakant Vittal Shetty, Anand Vittal Shetty and Reji Verghese, all linked to Zorvia Healthcare and its associated corporate structure.
According to the prosecution, the FIR was registered following a complaint by Emcure Pharmaceuticals’ chief financial officer, alleging that former stakeholders of Zuventus Healthcare violated contractual obligations and engaged in unfair competitive practices. The complaint further alleges that a rival entity was floated in November 2025, triggering large-scale movement of employees and sensitive information.
The sessions court, while hearing the matter, observed that the allegations were serious in nature, noting that the FIR involves cheating charges exceeding ₹74 crore. The court also recorded submissions from both sides, including arguments that the dispute is primarily commercial and already subject to parallel civil proceedings. The matter has been posted for further hearing on June 2, after issuing notice to the prosecution.
Registration Begins for FutureCrime Summit 2026, India’s Largest Cybercrime Conference
Mass Employee Exits and Operational Disruptions
As per the complaint, nearly 950 employees from departments including HR, IT, legal, marketing and sales allegedly resigned between October and December 2025 and joined the rival firm. This alleged mass exit is claimed to have disrupted operations and impacted business continuity across multiple verticals of the pharmaceutical company.
Investigators have also alleged that confidential commercial data, product details, export records and research material were transferred to personal email accounts. A technical audit reportedly indicated that intellectual property and research and development data worth over ₹100 crore was deleted or misused, forming a key part of the ongoing probe.
The FIR further states that Zuventus Healthcare suffered a reported sales decline of ₹74.96 crore between October 2025 and March 2026, along with monthly revenue losses estimated between ₹7 crore and ₹10 crore. These losses are attributed to alleged employee attrition and the subsequent disruption in business operations following the formation of the rival company.
Shareholders’ Agreements and Private Severance Frameworks
At the heart of the dispute is a shareholders’ agreement signed in 2002, which allegedly contained strict non-compete and non-solicitation clauses. The complainant has argued that these clauses were breached, leading to unfair competition and misuse of sensitive corporate information.
The accused have argued before the court that the matter is fundamentally a commercial dispute and that criminal proceedings are being misused to exert pressure. Their legal counsel has also pointed out that related civil proceedings are already pending before other judicial forums.
The court, however, noted that the seriousness of allegations requires detailed examination before granting any interim protection. The prosecution has opposed anticipatory bail, arguing that custodial interrogation may be necessary to uncover the full extent of alleged data transfer and financial impact.
Corporate Governance Friction and Custodial Demands
Meanwhile, the EOW continues its investigation into digital records, email communications and financial transactions linked to the accused entities. Officials are also examining whether sensitive intellectual property was deliberately diverted to competing business platforms.
Legal experts say the case highlights increasing friction between corporate governance frameworks and criminal law enforcement in disputes involving intellectual property and employee mobility. The outcome of the bail hearing is expected to shape the next phase of the investigation, as the court weighs competing claims of commercial dispute versus alleged criminal wrongdoing.
